Cyto Sorbents Corporation
Medical Devices, 7 Deerpark Dr, Princeton, New Jersey, 08852, United States, 201-500 Employees
Phone Number: 17*********
Who is CYTOSORBENTS CORPORATION
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption technology. Cyt...
Read More
-
Headquarters: 7 Deerpark Dr, Princeton, New Jersey, 08852, United States
-
Date Founded: 2012
-
Employees: 201-500
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
-
CEO:
Phillip Chan
Email
Phone
Industry: Medical Devices
SIC Code: 3841
|
NAICS Code: 339112 |
Show More
Does something look wrong? Fix it. | View contact records from CYTOSORBENTS CORPORATION
CytoSorbents Corporation Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding CytoSorbents Corporation
Answer: CytoSorbents Corporation's headquarters are located at 7 Deerpark Dr, Princeton, New Jersey, 08852, United States
Answer: CytoSorbents Corporation's phone number is 17*********
Answer: CytoSorbents Corporation's official website is https://cytosorbents.com
Answer: CytoSorbents Corporation's revenue is $50 Million to $100 Million
Answer: CytoSorbents Corporation's SIC: 3841
Answer: CytoSorbents Corporation's NAICS: 339112
Answer: CytoSorbents Corporation has 201-500 employees
Answer: CytoSorbents Corporation is in Medical Devices
Answer: CytoSorbents Corporation contact info: Phone number: 17********* Website: https://cytosorbents.com
Answer: CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption technology. CytoSorbents is a leader in the treatment of life-threatening conditions in the ICU and cardiac surgery using blood purification. Its flagship product, CytoSorb, is distributed in more than 70 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorbents has multiple active, clinical trials ongoing, including two pivotal randomized, controlled trials in the United States designed to support eventual FDA marketing approval for antithrombotic removal during cardiothoracic surgery using the DrugSorbTM-ATR Antithrombotic Removal System.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month